Mucormycosis is a deep invasive mycotic infection caused byMucorales fungi and typically affects people with a weakened immune system [1]. The most common conditions that predispose patients to mucormycosis are diabetes mellitus with or without ketoacidosis, hematological or other malignancies, transplantation, iron overload, corticosteroid use, trauma, prolonged neutropenia, and malnutrition [2]. The mode of contamination is the inhalation of fungal spores [3]. The infection can spread to the orbital and intracranial structures either by direct invasion or through the blood vessels. Oral mucormycosis usually affects the paranasal sinuses or nasal area, and severe infection of the paranasal sinuses can lead to palatal necrosis and/or ulceration [4]. Warning signs include cranial nerve palsy, sinus pain, proptosis, diplopia, periorbital edema, orbital apex syndrome, and palatine ulceration. Any of these symptoms should prompt additional testing, such as blood tests, imaging, exploratory ocular and/ or sinus surgery, diagnostic endoscopy, and the start of antifungal therapy [5].Uncontrolled diabetes mellitus is a major risk factor for mucormycosis [6]. Even patients who have a well-controlled diabetes with no underlying immunosuppressant risk factors are still at risk for mucormycosis infection [7]. Traditionally considered rare, this invasive fungal infection is beginning to become a concern in the COVID-19 pandemic era and with the increasing prevalence of diabetes globally [3]. Medical professionals are also facing additional challenges in the early diagnosis and treatment of this invasive fungal infection during the current COVID-19 pandemic.Among the medical professionals involved in managing patients with mucormycosis, maxillofacial prosthodontists are responsible for prosthetic restoration of lost oral and maxillofacial structures, helping patients to socialize and have an acceptable quality of life after surgical treatment. The purpose of this review is to raise awareness about the expected increase in mucormycosis cases, the associated morbidities, and the role played by maxillofacial prosthodontists in rehabilitation during the COVID-19 pandemic.